Akers Biosciences Share Discussion Threads

[rivaldo] 11/9/2014 12:00

Nice interview - I too liked the sound of the $5m sales from the cholesterol test over the next 12-24 months.

Do you think the colour of the presenter's hair is natural :o))

[rivaldo] 11/9/2014 06:51

AKR finished at $4.55 in the USA according to this - don't know what happened with the blip above $7, but probably just a fat fingered rogue trade or similar:



Mcmather, thx for the Youtube link, will watch later.

[mcmather] 10/9/2014 23:09

Have a butchers at this chart / link to Akers chart on the nasdaq site re the share price having gone above $7 ($7.20?) around / after the close.



See what happens tomorrow but $7.20 is around £4.44.

[mcmather] 10/9/2014 22:55

Just uploaded; our mate dave at redchip:



$5m sales from the tri-cholesterol device over next 12-24 months....

Re-iteration that Breath Ketone is approved in Europe and they are "just introducing now" in Europe.

Konica Minolta - $1bn year in diagnostics products in Asia alone - selected Akers to develop first test that will diagnose a heart attack in real time. "Absolutely huge"???

Here's another video to follow the above; the eyes have it....

[mcmather] 10/9/2014 22:38

Don't know what happened with the nasdaq price there but everything suggests that the closing price was around $4.55 (£2.80ish).


2014 is looking like a transformational year for point-of-care testing specialist Akers Biosciences. In January, the firm floated on the Nasdaq Capital Market, raising $15m and, in March, it appointed co-founder Raymond Akers CEO, replacing Thomas ...
You need to sign up for the interview


Akers Biosciences rocketed 52.5p to 267.5p after announcing an $864,000 contract for sales of its three-minute cholesterol test in Australia, Singapore, UAE and Oman. Its executive chairman, Raymond Akers, said: “This order gives us confidence that this test could become a very important and widely used test worldwide.”

[mcmather] 10/9/2014 21:04

Bit of competition re lung cancer detection device?

A breath test that detects early signs of lung cancer and lowers the disease's death rate could be used by the NHS.



Re nasdaq, reference to share price 'doubling' from the recent lows:

[mcmather] 10/9/2014 16:49

Volume today nearly 1/4million? X £2.75...

[rivaldo] 10/9/2014 16:29

Nice - looks like a 60k buy just reported at 275.82p.

[mcmather] 10/9/2014 16:23

And in the midst of all this the share price continues to rise. Bizarre but still welcome.

[waylander2] 10/9/2014 16:07

This isn't the first time they have announced something months after it happened. If you remember the results a couple of years ago TN mentioned the loss of the breathalyser contract to the US Army even though that had happened over 18 months prior. I really never cease to be amazed by this company :-(

[norbus] 10/9/2014 14:59

Oh dear! Maybe that is why Tom Left? There is a lady in marketing, can't recall her name; If she has gone, then things are more dodgy than straight.

[mcmather] 10/9/2014 12:38

Still a bit smoke and mirrors Norbus; if you remove this contract from H1 2014 then the figures were extremely poor but especially with sales of chube 'flat-lining'.

Did they therefore include this order to perk up H1 figures?

If not, why was it not announced in H1?

Why has it been 'announced' now after it has already been announced??

Think they already had the stock from the failed contract with Al Tadawi 29 Dec 2010 (see cost of sales, etc):

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces a $1.65m order with Al Tadawi Medical Equip TR LLC ("Al Tadawi"), for ABI's Tri-Cholesterol "Check" tests

Strange how 'astute' business people cannot keep things simple; announce stuff when it should be announced - indeed was there a legal requirement for this to have been disclosed previously if already included in H1 figures? - and if you believe what you say re growth / shareholder value / etc then don't get greedy and upset investors both here but especially in the US with options either at the same figure or quite a bit below the IPO figure; you won't end up short in the long run.

[norbus] 10/9/2014 11:09

mcm

good for you; Tri-C is tricky, and the fancy hardest colestrol to get down. There is life in the old dog:-)

[rivaldo] 10/9/2014 09:30

AKR were also featured on Fox Business (and to be repeated on Bloomberg) last night by Redchip:



For some reason AKR's video isn't yet on Youtube like the others - I've e-mailed to find out why.

[mcmather] 09/9/2014 19:50

Norbus, which one are you going to? Or is it both of them??

Executive Chairman Raymond F. Akers Jr., Ph.D, to present at:

Rodman & Renshaw 16th Annual Global Investment Conference; and Aegis Capital Corporation 2014 Healthcare & Technology Conference

THOROFARE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company") a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that its Executive Chairman, Raymond F. Akers Jr., Ph.D, will present this week at the Rodman & Renshaw 16th Annual Global Investment Conference and the Aegis Capital Corporation 2014 Healthcare and Technology Conference.

The Rodman & Renshaw 16th Annual Global Investment Conference is being held at the New York Palace Hotel, New York City. The Company is scheduled to make its presentation on Wednesday, September 10 at 12:05 PM in Kennedy I Salon (4th floor); and is conducting one-on-one meetings throughout the day. For more information visit:

The Aegis Capital Corp. 2014 Healthcare and Technology Conference is being held at the Encore and Wynn Las Vegas. The Company is scheduled to make its presentation on Friday, September 12 at 09:00 AM in Chopin 2; and is conducting one-on-one meetings throughout the day. For more information visit:

[mcmather] 09/9/2014 16:22

Slightly bizarre reaction to something that was highlighted on here nearly 1 month ago - post #2451.

Anyhow, if this can be followed up with some other pieces of 'news' - typenex (US) / Medline (US) / Novotek (China) / EU (Nicolas Daurel's recent appointment) / Jai Capital LLC (India) / etc - that would hopefully make things a little more interesting.

[rivaldo] 09/9/2014 13:39

This confirms my opinion that AKR has absolutely huge potential for an £11m m/cap company trading at not far above net cash.

And this is just one of AKR's portfolio of current or upcoming commercially available tests.

Mcm, today's RNS confirms that "Revenue related to this order for Tri-Cholesterol "Check" tests (a Rapid Enzymatic Assay product) was recognized in the accounts for the six months ended June 30, 2014", so it's fairly clear that this is one and the same order.

I suspect that either (a) somehow the initial "order" has now been formalised in some way, or (b) the details as to which markets the tests were being supplied to were initially confidential in some way and have now received clearance for publication.

[mcmather] 09/9/2014 12:57

Notwithstanding any bona fide (or not) arguments re medical / efficacy needs, etc, the target market covered by 36S does appear promising:

"Target customers in Australia, Singapore, the United Arab Emirates and Oman include military forces, medical associations, universities and large companies operating in the resources sector"

[mcmather] 09/9/2014 12:50

Didums bellwhiff.

[mcmather] 09/9/2014 12:47

Not clear whether this is an additional order to that which was detailed within the H1 2014 results?? If not, why formally announce it now - perhaps a 'contract' as opposed to an 'order' - if reference has already been made / announced in the half yearly results which stated:

""Revenue from Rapid Enzymatic Assay ("REA") products in the six months ended June 30, 2014 totaled $864,000 (2013: $-). This revenue is attributable to the Company's new distributor in Australia, Singapore, Oman and the United Arab Emirates, Thirty Six Strategies General Trading LLC ("36S"), which placed its first order with the Company during the period."

[rivaldo] 09/9/2014 11:24

Good to see the price bouncing nicely after a 2k buy at 230p. Perhaps this means our overhang has gone.

[mcmather] 08/9/2014 19:13

Notwithstanding that those options stink, why have those who have been awarded such not decided to buy shares at this level which is below the level of the options??

Only one member of the management team has acquired of late and that was only £2K's worth.

That is poor form in my opinion. They could get the options rescinded - certainly those at $3.98 - buy a similar amount at this level, appease shareholders (to a degree) and also provide a vote of confidence in themselves and the company.

Doing the opposite would send out what kind of a signal in terms of their self-belief / competencies?

[mcmather] 08/9/2014 12:10

Lets hope so rivaldo; the thread on here re DS certainly made 'interesting' reading.